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ARTICLE
Ki-67 is an independent predictor of prostate cancer death in
routine needle biopsy samples: proving utility for routine
assessments
Solène-Florence Kammerer-Jacquet1,2 ● Amar Ahmad3 ● Henrik Møller4 ● Holly Sandu3 ● Peter Scardino5 ●
Geraldine Soosay6 ● Luis Beltran1 ● Jack Cuzick3 ● Daniel M. Berney1
Abstract
Standard clinical parameters fail to accurately differentiate indolent from aggressive prostate cancer. Our previous studies
showed that immunohistochemical testing for Ki-67 improved prediction of prostate cancer death in a previous cohort of
conservatively treated clinically localized prostate cancer. However there is a need for validation of usage with whole biopsy
sections rather than tissue micro-arrays for use in routine diagnostics. Prostate cancer biopsy cases were identified in the UK,
between 1990 and 2003, treated conservatively. Tumor extent and prostate-specific antigen (PSA) serum measurements were
available. Biopsy cases were centrally reviewed by three uropathologists and Gleason conformed to contemporary ISUP
2014 criteria. Follow-up was through cancer registries up until 2012. Deaths were divided into those from prostate cancer
and those from other causes. The percentage of Ki-67 in tumor cells was evaluated by immunohistochemistry on whole
biopsy sections and was available for 756 patients. This percentage was used in analysis of cancer specific survival using a
Cox proportional hazards model. In univariate analysis, the interquartile hazard ratio (HR) (95% confidence intervals) for
continuous Ki-67 was 1.68 (1.49, 1.89), χ1
2= 47.975, P < 0.001. In grade groups 1 and 2, continuous Ki-67 was a
statistically significant predictor of time to death from prostate cancer, HR (95% CI)= 1.97 (1.34, 2.88), χ12= 9.017, p=
0.003. In multivariate analysis, continuous Ki-67 added significant predictive information to that provided by grade groups,
extent of disease and serum PSA, HR (95% CI)= 1.34 (1.16, 1.54), Δχ12= 13.703, P < 0.001. We now advocate the
introduction of Ki-67 as a viable and practicable prognostic biomarker in clinical practice. The association of Ki-67 with
mortality was highest in grade groups 1 and 2, showing that Ki-67 can be used as a routine biomarker in patients being
considered for active surveillance.
Introduction
Prostate cancer remains the most common non-cutaneous
malignancy in men. However many patients do not require
radical treatment and will die from unrelated causes. Con-
sequently a significant proportion of patients undergo
radical treatment without need [1, 2]. Conversely, some
patients will fail treatments notwithstanding the use of
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combined modality approaches [3]. Therefore decision
making in early prostate cancer remains difficult even using
current the clinical parameters of serum prostate-specific
antigen (PSA), routine histopathology, imaging and patient
age and performance status.
In spite of extensive research, few molecular markers
have been translated into routine use in genito-urinary
oncology. Any new biomarker must give further predictive
ability beyond that available by using current known, easily
measured parameters, and the data must differentiate
patients into groups for which different options can be
selected from active surveillance to radical treatment.
The most promising immunohistochemical biomarker
identified for prostate cancer is Ki-67, a cell proliferation
marker, expressed in G1, S, G2 and M phases of the cell cycle
being absent in resting cells (G0). As the grading system in
prostate cancer is pattern based and does not consider the
proliferation rate of the cells, it is possible that measuring the
cell proliferation rate in prostate tumors could yield additional
prognostic information. Ki-67 has been shown to be an
independent predictor of prostate cancer outcome in a large
number of studies on systematic review [4].
Our previous work, on the Trans-Atlantic Prostate Group
cohort of conservatively managed prostate cancers diag-
nosed by transurethral resection of the prostate and needle
biopsies showed that Ki-67 was an independent prog-
nostically significant marker when PSA, Gleason score, and
tumor extent were also considered [5, 6]. However, this
cohort included many transurethral resection of the prostate
patients, and biopsy patients were often sub-optimally
sampled. Also these and other studies utilize tissue micro
arrays and do not reflect the methods, which will be used in
routine pathology laboratories to assess Ki-67.
Our hypothesis was that immunohistochemical assess-
ment of Ki-67, in a conservatively treated cohort, would be
of independent prognostic value with prostate cancer death
at the end point, using a methodology which could be
directly translated to routine pathology laboratories and thus
into clinical use.
Materials and methods
Patients
Cases of prostate cancer were identified from three cancer
registries in Great Britain. Within each region, collaborating
hospitals were sought and cases from these hospitals were
reviewed. Men were included in this study if they were
under age 76 years at the date of diagnosis and had clini-
cally localised prostate cancer diagnosed by needle biopsy
between 1990 and 2003 inclusively. The median date of
diagnosis was May 2002. Patients treated by radical
prostatectomy or radiation therapy within 6 months of
diagnosis were excluded. In addition, those with objective
evidence of metastatic disease (by bone scan, X-ray,
radiograph, CT scan, MRI, bone biopsy, lymph node biopsy
and pelvic lymph node dissection) or clinical indications of
metastatic disease (including pathologic fracture, soft-tissue
metastases, spinal compression, or bone pain), or a PSA
measurement over 100 ng ml/1 at or within 6 months of
diagnosis were also excluded. Men who had hormone
therapy before the diagnostic biopsy were also excluded,
because of the influence of hormone treatment on Gleason
pattern. We also excluded men who died within 6 months of
diagnosis, or had <6 months of follow-up. Follow-up was
conducted through the cancer registries and the cut-off date
was 31 December 2012. Deaths were divided into those
from prostate cancer and those from other causes, according
to World Health Organisation standardised criteria (WHO,
2010). National ethics approval was obtained from the
Northern Multicenter Research Ethics Committee, followed
by local ethics committee approval at each of the colla-
borating hospitals.
Histology
Original histological specimens from the diagnostic proce-
dure were requested and centrally reviewed by a panel of
three expert urological pathologists to confirm the diagnosis
of adenocarcinoma and to reassign Gleason score using of a
contemporary and consistent interpretation of the Gleason
scoring system [7, 8] and reclassified into grade groups [8].
KI-67 immunohistochemistry
Diagnostic formalin-fixed paraffin-embedded needle biopsy
tissue blocks and slides were requested. Biopsies showing the
highest Gleason grade were selected. Corresponding sections
were immunoassayed for Ki-67 using MIB-1 antibody,
DAKO, Carpinteria, CA, USA, and attempted to reduce pre
analytical variables by following recommendations used in
the assessment of Ki-67 in breast cancer by using the
recommended methods and platforms [9]. Briefly, cells were
scored in a semi-quantitative manner, by an expert prostatic
pathologist, and the mean percentage of positive cells was
estimated as the proportion of Ki-67 stained malignant cells,
in a manner similar to that used in routine pathology
departments for the assessment of proliferation index in other
organs [9, 10]. Corresponding H&E slides were simulta-
neously reviewed. All nuclear immunostaining was recorded
as positive and was clearly either strongly positive or nega-
tive. Normal tonsil was used as a positive control. The tech-
nique was designed to be robust for any pathology laboratory
with experience in immunohistochemistry and allow results to
be directly comparable to our previous work.
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Statistical analysis
Univariate and multivariate analysis was performed using a
Cox proportional hazards model with the primary end point
of analysis defined as death from prostate cancer. Obser-
vations stopped either on the date of death from other
causes or on the date of last follow-up. Covariates included
were age at diagnosis, grade groups, Ki-67 average, base-
line PSA value (defined as last pre-diagnostic PSA mea-
surement within 6 months before diagnosis), extent of
disease (percentage of positive cores). Receiver operating
characteristic curve analysis was performed at ten-year
survival to assess the predictive cut-off value for Ki-67
expression used to analyse Ki-67 as a binary variable. All p-
values were two-sided with significance set at α < 0.05.
Statistical analyses were performed using R (version 3.4.3,
The R Foundation for Statistical Computing, Vienna,
Austria).
Results
Cohort characterization
A total of 756 patients were available for analysis. Out of
them, 294 patients received no initial therapy, while 462
received early hormonal therapy only as an initial treatment.
The mean, median and interquartile range of patient age,
grade groups, serum PSA and extent of disease is shown in
Table 1. Follow-up for prostate cancer death was until 31
December 2012 with 145 (20%) patients who died from
their cancer. The median follow-up time was 9.6 years
(IQR: 11.2-6.6).
Ki-67 expression
The mean percentage of Ki-67 was 5%, 53 (7%) scored as
less than 1%, 429 (57%) as between 2 and 5%, 175 (23%) as
between 6 and 10% and 99 (13%) as more than 10 (Fig. 1 and
Supplementary Figure). The majority of deaths n= 80 (55%)
were in the high Ki-67 groups (>5%, n= 274). The Receiver
Operating Characteristics curve analysis (AUC= 0.685, 95%
CI: 0.637–0.738) identified 5% as the most predictive cut-off
value for Ki-67 expression with a sensitivity of 60% and a
specificity of 69%. This cut-off was subsequently used in
univariate and multivariate analysis (Fig. 2).
Univariate analysis
In univariate analysis, grade groups, PSA, extent of disease
and Ki-67 were all significant predictors of prostate cancer
death (Ki-67: HR= 1.68, 95% CI: 1.49–1.89), but not the
age of patient (Table 2). Kaplan–Meier cancer specific
Table 1 Distribution of variables in the needle biopsy cohort
Variable Median (IQR) or n(%)
Patient’s age (years) 70.93 (66.77–73.61)
Grade group (GG)
GG1 181 (24)
GG2 246 (33)
GG3 179 (24)
GG4 49 (6)
GG5 101 (13)
PSA (ng/ml per 10%) 1.57 (3.44–0.85)
Extent of disease (per 10%) 5.56 (8.57–3.33) Fig. 1 Distribution of Ki-67% staining in cases, n= 756
Fig. 2 Survival Receiver Operating Characteristics curve at 10 years.
The sensitivity (95% CI) and specificity (95% CI) were reported for a
cut-off value of 2 (black square), 5 (black circle) and 10 (black tri-
angle) of the Ki-67. All 95% confidence intervals (CI) were based on
1000 bootstrap replicates
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survival curves for Ki-67 in two groups (≤5 or >5%) and
showed significant difference between the two groups with
an HR= 2.65 (95% CI (1.91–3.69), log-rank test= 33.46,
p= 7.3 × 10−09), Fig. 3. Ki-67 was stratified by grade
groups using Forest plot graphing (Fig. 4). It was found that
the most predictive Ki-67 information was in grade groups
1 and 2 compared to the other groups (HR= 1.1, 95% CI:
1.04–1.16).
Multivariate analysis
In multivariate analysis, continuous and dichotomous Ki-67
variables added significant predictive information to that
provided by grade groups and PSA alone (continuous Ki-
67: HR= 1.34, 95% CI: 1.16, 1.54, Ki-67 5%: HR= 1.79,
95% CI: 1.27, 2.53). The covariates extent of disease and
PSA were slightly less informative (Table 2).
Discussion
The growing evidence concerning prostate cancer over-
diagnosis and over-treatment emphasizes the need for
accurate disease aggressiveness stratification [2]. Owing to
limitations of standard clinicopathological and biological
parameters, there is an unmet need for robust biomarkers
that may assist clinicians in deciding therapeutic strategy.
Ki-67 is an attractive biomarker from a technical per-
spective due to its universal use and reproducible inter-
pretation compared to other prostatic tissue biomarkers [11].
Indeed, it is widely used in routine practice, affordable by
academic and non-academic histopathology departments,
and easy to measure in a semi-quantitative manner.
Immunochemistry has the advantage over other molecular
techniques that it is easily applied to paraffin-embedded
tissue and has a very low ‘failure’ rate, unlike fluorescence.
Interestingly, results of immunohistochemical analysis of a
single marker of cell proliferation, Ki-67, could correlate with
those of a commercially available cell-cycle progression score
(Prolaris®), a molecular test that evaluates RNA signature of
several cell-cycle progression genes, as one of the cell-cycle
progression genes codes for Ki-67 [12]. If this hypothesis is
validated, Ki-67 immunohistochemistry, with easier and
broader worldwide implementation, well-established analy-
tical performance, and reduced costs could help select patients
for those the molecular test is relevant.
Several studies have reported Ki-67 as an independent
prognostic factor for prostate cancer. Nevertheless, there is a
considerable heterogeneity among studies, including dif-
ferent endpoints, cohort types, sample sizes and cut-offs.
The studies with cancer specific survival as an endpoint are
compared in Table 3 [5, 6,13–20].
Table 2 Univariate and multivariate analysis for time to death from prostate cancer in a conservatively managed needle biopsy cohort
Variable Univariate Multivariate
IQRa HR (95%CI) LR χ1
2 p-value c-indexb IQRa HR (95%CI) LR χ1
2c p-value
Grade group 1.68 (1.50, 1.89) 74.56 <2.2a10−16 0.716 1.38 (1.20, 1.59) 74.56 <2.2a10−16
Ki-67 (continuous) 1.68 (1.49, 1.89) 47.97 4.3a10−12 0.665 134 (1.16, 1.54) 19.85 8.38a10−06
Extent 3.21 (2.35, 4.38) 59.96 97a10−15 0.690 1.74 (1.21, 2.50) 14.29 0.0002
PSA 1.66 (1.43, 1.93) 36.90 1.24a10−09 0.660 1.16 (0.98, 1.38) 2.77 0.096
Age 1.17 (0.93, 1.47) 1.81 0.178 0.527
LR χ42 (p-value) 111.469 (<2e-16)
c-indexb (95%CI) 0.757 (0.707, 0.808)
aInterquartile-range hazard ratios for continuous predictors and simple hazard ratios for categorical predictors
bHarrell’s c-index
cTerms added sequentially (first to last)
Fig. 3 Kaplan–Meier estimates of prostate cancer death according to
Ki-67 (negative: ≤5 and positive: >5) at10-year death rate from pros-
tate cancer
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To our knowledge, our multicentre study is the largest
to assess the prognostic impact of Ki-67 in a cohort of
diagnostic biopsies. In our previous cohort including
conservatively managed patients, we demonstrated the
discriminatory value of Ki-67 on transurethral resection
of the prostate and needle biopsies [5, 6]. However,
this current cohort is larger, clinically more con-
temporary with Gleason grade reviewed according to
last ISUP recommendations [21] and confirmed our first
results.
Fig. 4 Forest plot graphing the
Ki-67 hazard ratio in different
grade groups
Table 3 Published reports of the prognostic value of Ki-67 in multivariate analyses with hazard ratio’s (HR) after adjument for covariates with
prostate cancer-survival as end point
Reference Cohort type Cohort size Cutoff (%) p-value HR (95% CI) Covariates
Stattin et al. [13] TURP, WW 125 3 0.0023 2.51 (1.39–4.53) G T A
Li et al. [14] RX 108 3.5 0.009 4.24 (1.43–12.57) G T Tx
Pollack et al. [15] RX 496 cont 0.001 3.64 (2.15–6.16) G T P Tx
Pollack et al. [15] RX 496 7.1 0.0174 2.07 (1.14–3.76) G T P Tx
Berney et al. [5] TURP, WW 685 5 0.0003 1.83 (1.33–2.53) G P Px
Khor et al. [16] RX 637 11.3 0.0007 2.35 (1.43–3.85) G T A Tx
Fisher et al. [6] BX, WW 293 10 0.011 2.66 (1.36–5.2) G P
Verhoven et al. (2013) BX RX 468 6.2 0.0064 2.91 (1.35–6.26) A G P T
Tollefson et al. [17] BX 451 cont 0.001 1.11 (1.07–1.15) G Px
Tretiakova et al. [18] RP 1004 cont 0.02 1.10 (1.02–1.18) G P Px
Tretiakova et al. [18] RP 1004 5 ns G P Px
Lobo et al. [19] BX 189 5.33 <0,05 1.91 (1.01–3.57) A G T
Kammerer-Jacquet et al. (this paper) BX, WW 756 cont 0.001 1.08 (1.06–1.10) A E G P
Kammerer-Jacquet et al (this paper) BX, WW 756 5 0.007 1.93 (1.32–2.81) A E G P
A age, BX needle biopsy, CI confidence interval, CONT continuous, E extent, G Gleason grade, ns not significant, P prostate-specific antigen, PCS
prostate cancer-specific survival, PCR prostate cancer recurrence, Px pathological features, RP radical prostatectomy, RX radiotherapy, T clinical
stage, Tx treatment, TURP transurethral resection of the prostate, WW watchful waiting
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In this study, we performed Ki-67 on needle biopsies
instead of radical prostatectomies or transurethral resection
of the prostate specimens to approach conditions for clinical
decision before any treatment. The assessment of Ki-67 on
the whole slides rather than tissue micro arrays reflects
routine use and avoids potential bias due to tumor hetero-
geneity. Indeed, studies comparing the assessment of Ki-67
on tissue micro arrays and on whole slides recommended
the use of the latter [22, 23].
The Ki-67 cut-off varies from a study to another. In our
series, we identified 5% Ki-67 as the most relevant cut-off
given the results of our cut-point analysis (Receiver Operating
Characteristics curve). This cut-off aligns with the most fre-
quently used level, fixed around 5–10% [4, 5, 18, 24] and the
difference may be explained by the constitution of the cohort,
the material or the method of assessment. In addition,
Kaplan–Meier plots confirmed robust curve separation
between low and high Ki-67 groups at 5% cut-off.
For the first time, we report a subgroup analysis of Ki-67
prognostic impact in grade groups. Ki-67 was the most
discriminatory in grade groups 1 and 2 compared to higher
grade groups (Forest Plot). These low-grade groups with the
best prognosis are frequently included in active surveillance
studies [25]. For these patients, Ki-67 expression could help
discriminate the most aggressive from the majority of
indolent cancers.
The weaknesses of our study include its retrospective
nature and the use of cases dating from 1990 to 2003.
Nevertheless, only long follow-up time enables appropriate
assessment of cancer specific survival that was our endpoint.
Metastasis free survival would have been a useful addition
that is missing in our study. However, cancer specific survival
is a major endpoint for any biomarker and is reproducible to
compare studies. In needle biopsies cohort, the amount of
cancer available in needle biopsies can be limited that could
impact tumor representativeness and the assessment of mul-
tifocality. The immunohistochemistry itself has several lim-
itations including the antibody, preanalytic and analytic steps
lowered by its worldwide use in several other tumors and its
reproducible interpretation [10].
Ki-67 was mostly assessed by one pathologist. However,
the inter-observer concordance in Ki-67 assessment is good
and could be further improved by the use of cut-offs [10]. In
addition, visual scoring of Ki-67 and corresponding H&E
slide was used instead of digital scoring as inflammation and
high grade PIN in prostate biopsies are frequent pitfalls. In
particular, inflammatory cells are frequently stained by Ki-67
immunohistochemistry and included in digital analysis. In
addition, the two different approaches were compared in
prostate cancer with a high inter-correlation agreement [26].
In conclusion, Ki-67 immunoexpression independently
predicted prostate cancer patient outcome, adjusted for
standard clinico-pathological parameters, in a cohort of
diagnostic biopsies. If incorporated into routine practice,
this assessment might assist clinicians in discriminating the
most aggressive prostate cancer, improving treatment
selection especially in low-grade cancer. Nevertheless,
owing to the limitations of this study, a prospective vali-
dation of our findings in independent series is required to
confirm its clinical utility.
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